pirtobrutinib,rituximab,venetoclax
roche,eli lilly,abbvie
['bruin study', 'cll', 'pirto', 'bruin']
dr. nirav shah presents updated data from pts with richter syndrome (rs) tx'ed w/ pirtobrutinib on the phase-1/2 bruin study. 75 pts w/ rs evaluable by lugano criteria, 68 w/prior tx (0-13 prior rt tx), 52% orr (13% cr). median dor 5.4m in those w/ prior tx. #cllsm #ash22 
Leukemia/cell therapy doc & AYA Leukemia Program Leader at @MSKCancerCenter w/ special interest in ALL. Indie rock & Boston sports fan. Opinions=my own.??????